Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Study Identifier
GMA-US-OAB-0403
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
N/A
Sex
Female & Male
Age
18+ years
Protocol Summary
This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.
Study Locations
Location
Status
Location
University of California, Davis
Davis, California, United States, 95616
Status
Not applicable
Location
Capital Region Urology
Irvine, California, United States, 92612
Status
Not applicable
Location
The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System
Charlotte, North Carolina, United States, 28203
Status
Not applicable
Location
Alliance Urology Specialists, PA
Greensboro, North Carolina, United States, 27403
Status
Not applicable
Location
Forsyth Memorial Hospital Inc. dba Novant Health Urology Partners
Winston-Salem, North Carolina, United States, 27103
Status
Not applicable
Location
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109
Status
Not applicable
Showing {first} - {last} of {total} Results